(Q46941755)

26 December 2017

title

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer (English)

1 reference

26 December 2017

1 reference

Seung Tai Kim

1

1 reference

26 December 2017

Joon Oh Park

2

1 reference

26 December 2017

Jeeyun Lee

3

1 reference

26 December 2017

Kyu Taek Lee

4

1 reference

26 December 2017

Jong Kyun Lee

5

1 reference

26 December 2017

Seong-Ho Choi

6

1 reference

26 December 2017

Jin-Seok Heo

7

1 reference

26 December 2017

Young Suk Park

8

1 reference

26 December 2017

Won Ki Kang

9

1 reference

26 December 2017

Keunchil Park

10

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

26 December 2017

published in

Cancer

1 reference

26 December 2017

volume

106

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

1339-1346

1 reference

26 December 2017

Worldwide trends in mortality from biliary tract malignancies

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Resection of intrahepatic cholangiocarcinoma: a Western experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Basis for effective combination cancer chemotherapy with antimetabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Surgical treatment of cholangiocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Review of gemcitabine in biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21741

7 January 2021

Identifiers

DOI

10.1002/CNCR.21741

1 reference

26 December 2017

1 reference

26 December 2017